A note on the ring current in Saturn's magnetosphere: Comparison of magnetic data obtained during the Pioneer-11 and Voyager-1 and -2 fly-bys

International audienceWe examine the residual (measured minus internal) magnetic field vectors observed in Saturn's magnetosphere during the Pioneer-11 fly-by in 1979, and compare them with those observed during the Voyager-1 and -2 fly-bys in 1980 and 1981. We show for the first time that a ring current system was present within the magnetosphere during the Pioneer-11 encounter, which was qualitatively similar to those present during the Voyager fly-bys. The analysis also shows, however, that the ring current was located closer to the planet during the Pioneer-11 encounter than during the comparable Voyager-1 fly-by, reflecting the more com-pressed nature of the magnetosphere at the time. The residual field vectors have been fit using an adaptation of the current system proposed for Jupiter by Connerney et al. (1981a). A model that provides a reasonably good fit to the Pioneer-11 Saturn data extends radially between 6.5 and 12.5 RS (compared with a noon-sector magnetopause distance of 17 RS), has a north-south extent of 4 RS, and carries a total current of 9.6 MA. A corresponding model that provides a qualitatively similar fit to the Voyager data, determined previously by Connerney et al. (1983), extends radially between 8 and 15.5 RS (compared with a noon-sector magnetopause distance for Voyager-1 of 23?24 RS), has a north-south extent of 6 RS, and carries a total current of 11.5 MA

Prevalence and main outcomes of placenta accreta spectrum: a systematic review and metaanalysis

OBJECTIVE: The objective of this study was to evaluate the prevalence of placenta accreta spectrum in general population studies and the main maternal outcomes at delivery. STUDY DESIGN: Data sources: We searched PubMed, Google Scholar, clinicalTrials.gov and MEDLINE between 1982 and 2018. STUDY ELIGIBILITY CRITERIA: Articles providing data on the number of cases of placenta accreta spectrum per pregnancies, births or deliveries in a defined population. STUDY APPRAISAL AND SYNTHESIS METHODS: Study characteristics were evaluated by two independent reviewers using a predesigned protocol. Primary outcomes were the prevalence of placenta accreta spectrum and clinical diagnostic at birth and pathologic criteria used to confirm the diagnosis. Secondary outcomes included cases requiring transfusion, incidence of peripartum hysterectomy and maternal mortality rates. Heterogeneity between studies was analysed with the Cochran's Q-test and the I2 statistics. RESULTS: Of the 98 full-text studies identified, 29 articles met the defined criteria including 22 retrospective and 7 prospective studies comprising 7,001 cases of placenta accreta spectrum out 5,719,992 births. Prevalence rates ranged between 0.01 and 0.1% with an overall pooled prevalence of 0.17% (95% CI 0.14-0.19). Only 10 studies provided with detailed histopathologic data. The pool prevalence for the adherent versus the invasive grades was 0.5 (95% CI 0.3-0.36) and 0.3 (95% CI 0.2-0.4) per 1000 births, respectively. The pooled incidence for peripartum hysterectomy was 52.2% (95% CI 38.3-66.4; I2= 99.8%) and 46.9% (95 % CI 34-59.9, I2= 98.8%) for haemorrhage requiring transfusion. The pooled estimate of maternal death was 0.05% (95% CI 0.06-0.69, I2=73%). We found large amounts of heterogeneity between studies for all parameters and further quantifying was limited because of methodological inconsistencies between studies with regards to clinical criteria used for the diagnosis of the condition at birth and the histopathologic confirmation of the diagnosis and differential diagnosis between adherent and invasive accreta placentation. CONCLUSIONS: This meta-analysis indicates wide variation between studies for the prevalence rate of placenta accreta spectrum and for the different grades of accreta placentation, highlighting the need for consistency in definitions used to describe placenta accreta spectrum at birth and in reporting on this increasing common obstetric complication

The Haematopoietic Stem Cell Niche: New Insights into the Mechanisms Regulating Haematopoietic Stem Cell Behaviour

The concept of the haematopoietic stem cell (HSC) niche was formulated by Schofield in the 1970s, as a region within the bone marrow containing functional cell types that can maintain HSC potency throughout life. Since then, ongoing research has identified numerous cell types and a plethora of signals that not only maintain HSCs, but also dictate their behaviour with respect to homeostatic requirements and exogenous stresses. It has been proposed that there are endosteal and vascular niches within the bone marrow, which are thought to regulate different HSC populations. However, recent data depicts a more complicated picture, with functional crosstalk between cells in these two regions. In this review, recent research into the endosteal/vascular cell types and signals regulating HSC behaviour are considered, together with the possibility of a single subcompartmentalised niche

Epidemiology of placenta previa accreta: a systematic review and meta-analysis

Objective To estimate the prevalence and incidence of placenta previa complicated by placenta accreta spectrum (PAS) and to examine the different criteria being used for the diagnosis. Design Systematic review and meta-analysis. Data sources PubMed, Google Scholar, ClinicalTrials.gov and MEDLINE were searched between August 1982 and September 2018. Eligibility criteria Studies reporting on placenta previa complicated by PAS diagnosed in a defined obstetric population. Data extraction and synthesis Two independent reviewers performed the data extraction using a predefined protocol and assessed the risk of bias using the Newcastle-Ottawa scale for observational studies, with difference agreed by consensus. The primary outcomes were overall prevalence of placenta previa, incidence of PAS according to the type of placenta previa and the reported clinical outcomes, including the number of peripartum hysterectomies and direct maternal mortality. The secondary outcomes included the criteria used for the prenatal ultrasound diagnosis of placenta previa and the criteria used to diagnose and grade PAS at birth. Results A total of 258 articles were reviewed and 13 retrospective and 7 prospective studies were included in the analysis, which reported on 587 women with placenta previa and PAS. The meta-analysis indicated a significant (p<0.001) heterogeneity between study estimates for the prevalence of placenta previa, the prevalence of placenta previa with PAS and the incidence of PAS in the placenta previa cohort. The median prevalence of placenta previa was 0.56% (IQR 0.39–1.24) whereas the median prevalence of placenta previa with PAS was 0.07% (IQR 0.05–0.16). The incidence of PAS in women with a placenta previa was 11.10% (IQR 7.65–17.35). Conclusions The high heterogeneity in qualitative and diagnostic data between studies emphasises the need to implement standardised protocols for the diagnoses of both placenta previa and PAS, including the type of placenta previa and grade of villous invasiveness. PROSPERO registration number CRD4201706858

Trends in diabetic retinopathy screening attendance and associations with vision impairment attributable to diabetes in a large nationwide cohort

AIMS: To investigate diabetic retinopathy screening attendance and trends in certified vision impairment caused by diabetic eye disease. METHODS: This was a retrospective study of attendance in three urban UK diabetic eye screening programmes in England. A survival analysis was performed to investigate time from diagnosis to first screen by age and sex. Logistic regression analysis of factors influencing screening attendance during a 15-month reporting period was conducted, as well as analysis of new vision impairment certifications (Certificate of Vision Impairment) in England and Wales from 2009 to 2019. RESULTS: Of those newly registered in the Routine Digital Screening pathway (n = 97 048), 80% attended screening within the first 12 months and 88% by 36 months. Time from registration to first eye screening was longer for people aged 18-34 years, and 20% were unscreened after 3 years. Delay in first screen was associated with increased risk of referable retinopathy. Although 95% of participants (n = 291 296) attended during the 15-month reporting period, uptake varied considerably. Younger age, social deprivation, ethnicity and duration of diabetes were independent predictors of non-attendance and referable retinopathy. Although the last 10 years has seen an overall reduction in vision impairment certification attributable to diabetic eye disease, the incidence of vision impairment in those aged <35 years was unchanged. CONCLUSIONS: Whilst the majority of participants are screened in a timely manner, there is considerable variation in uptake. Young adults, have sub-optimal attendance, and levels of vision impairment in this population have not changed over the last 10 years. There is an urgent need to explore barriers to/enablers of attendance in this group to inform policy initiatives and tailored interventions to address this issue

Discovery limits for a new contact interaction at future hadronic colliders with polarized beams

The production of high-transverse energy jets in hadron-hadroncollisions is sensitive to the presence of new contact interactions between quarks. If proton polarization were available, the measurement of some parity violating spin asymmetries in one-jet production at large transverse energy would complement the usual search for deviations from the expected QCD cross section. In the same time, a unique information on the chirality structure of the new interaction could be obtained. In this context, we compare the potentialities of various $pp$ and $p\bar p$ colliders that are planned or have been proposed, with the additional requirement of beam polarization.Comment: Latex file, 9 pages and 1 ps fig, definition of the subprocess variables and one example of the effect of new contact terms on the parity violating spin asymmetry are added. Eq. 8 (now eq. 9) and the following equation are changed, giving better bounds in the polarized pp case (new figure

Application of robotics In the clinical laboratory

The basic types of robot are explained, and the performances and costs of some commercial examples are given. The potential advantages and problems of introducing robots into clinical laboratories are identified and the specifcation of a suitable robot is developed. None of the commercially available robots meets all aspects of the specificalion, and currently the purchase of a robot is considered premature for most clinical laboratories